Abata Therapeutics' Treg Therapy ABA-101 Garners FDA Fast Track Designation
Abata Therapeutics' ABA-101, an autologous Treg therapy for progressive MS, received FDA fast track designation. It shows a tolerable safety profile and potential therapeutic effect, aiming to treat progressive MS patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.
Highlighted Terms
Related News
Abata Therapeutics' Treg Therapy ABA-101 Garners FDA Fast Track Designation
Abata Therapeutics' ABA-101, an autologous Treg therapy for progressive MS, received FDA fast track designation. It shows a tolerable safety profile and potential therapeutic effect, aiming to treat progressive MS patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.